SG10201609145PA - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents
Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditionsInfo
- Publication number
- SG10201609145PA SG10201609145PA SG10201609145PA SG10201609145PA SG10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA SG 10201609145P A SG10201609145P A SG 10201609145PA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazol
- ylmethyl
- tetrahydro
- quinoline
- conditions
- Prior art date
Links
- SIDBSMXMBWXFQV-UHFFFAOYSA-N 7-(1h-imidazol-5-ylmethyl)-5,6,7,8-tetrahydroquinoline Chemical compound C1CC2=CC=CN=C2CC1CC1=CNC=N1 SIDBSMXMBWXFQV-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558104P | 2011-11-10 | 2011-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201609145PA true SG10201609145PA (en) | 2016-12-29 |
Family
ID=47178364
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402246RA SG11201402246RA (en) | 2011-11-10 | 2012-11-08 | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| SG10201809506TA SG10201809506TA (en) | 2011-11-10 | 2012-11-08 | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| SG10201609145PA SG10201609145PA (en) | 2011-11-10 | 2012-11-08 | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402246RA SG11201402246RA (en) | 2011-11-10 | 2012-11-08 | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| SG10201809506TA SG10201809506TA (en) | 2011-11-10 | 2012-11-08 | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20130123303A1 (en) |
| EP (3) | EP3184110B1 (en) |
| JP (2) | JP6359456B2 (en) |
| KR (1) | KR102004563B1 (en) |
| CN (1) | CN104136029A (en) |
| AR (1) | AR088845A1 (en) |
| AU (2) | AU2012335803B2 (en) |
| BR (1) | BR112014011336A2 (en) |
| CA (1) | CA2855005C (en) |
| CL (1) | CL2014001242A1 (en) |
| DK (1) | DK2776034T3 (en) |
| ES (1) | ES2635421T3 (en) |
| IL (3) | IL232483B (en) |
| MX (1) | MX350662B (en) |
| MY (1) | MY182553A (en) |
| RU (2) | RU2667645C1 (en) |
| SG (3) | SG11201402246RA (en) |
| TW (3) | TW202014189A (en) |
| UA (1) | UA109359C2 (en) |
| WO (1) | WO2013070861A1 (en) |
| ZA (1) | ZA201403396B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| WO2014182610A2 (en) * | 2013-05-06 | 2014-11-13 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| FR3061434B1 (en) * | 2017-01-04 | 2019-07-12 | Pierre Fabre Dermo-Cosmetique | COSMETIC COMPOSITION COMPRISING AN ASSOCIATION OF PONGAMIA OIL AND PENTYLENE GLYCOL 4-T-BUTYLCYCLOHEXANOL FOR CONTROLLING ROSACEA |
| RU2727695C1 (en) * | 2020-02-13 | 2020-07-22 | Мурад Умарович Магомедов | Method of complex treatment of rhinophyma |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1676579E (en) * | 1998-05-08 | 2009-03-24 | Univ Miami | Use of sub-antimicrobial tetracyclines for treating ocular rosacea |
| US6242442B1 (en) * | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
| US20010049369A1 (en) * | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
| US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| US20040146539A1 (en) * | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| WO2005051328A2 (en) * | 2003-11-20 | 2005-06-09 | Othera Pharmaceuticals, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| EP2481412B1 (en) * | 2004-05-25 | 2017-09-27 | Galderma Pharma S.A. | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
| US20070203144A1 (en) * | 2006-01-17 | 2007-08-30 | Allergan, Inc. | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals |
| US7323477B2 (en) | 2006-02-02 | 2008-01-29 | Allergan, Inc. | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline |
| RU2321399C1 (en) * | 2006-06-01 | 2008-04-10 | Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" | Method for treating patients for rosacea |
| US20090005450A1 (en) * | 2007-04-09 | 2009-01-01 | Belinda Tsao Nivaggioli | Use of creatine compounds for the treatment of eye disorders |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| WO2009052073A2 (en) * | 2007-10-18 | 2009-04-23 | Allergan, Inc. | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists |
| EP2320911B1 (en) * | 2008-08-01 | 2014-10-08 | Eye Therapies LLC | Vasoconstriction compositions and methods of use |
| US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| FR2942138A1 (en) * | 2009-02-16 | 2010-08-20 | Galderma Res & Dev | ASSOCIATION OF COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DERMATOLOGICAL DISEASES |
| JP2013508454A (en) * | 2009-10-26 | 2013-03-07 | ガルデルマ ファルマ ソシエテ アノニム | Treatment or prevention of acute erythema |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| CN106038476B (en) * | 2010-03-26 | 2020-04-17 | 盖尔德马研究及发展公司 | Improved methods and compositions for safe and effective treatment of erythema |
| AU2011231544B2 (en) * | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| CN103140217B (en) * | 2010-08-06 | 2015-08-19 | 盖尔德马研究及发展公司 | Be used for the treatment of or prevent the combination of dermopathic compound |
-
2012
- 2012-08-11 UA UAA201406109A patent/UA109359C2/en unknown
- 2012-11-08 ES ES12784857.0T patent/ES2635421T3/en active Active
- 2012-11-08 KR KR1020147015533A patent/KR102004563B1/en active IP Right Grant
- 2012-11-08 SG SG11201402246RA patent/SG11201402246RA/en unknown
- 2012-11-08 SG SG10201809506TA patent/SG10201809506TA/en unknown
- 2012-11-08 CN CN201280065945.0A patent/CN104136029A/en active Pending
- 2012-11-08 JP JP2014541225A patent/JP6359456B2/en active Active
- 2012-11-08 RU RU2017131492A patent/RU2667645C1/en active
- 2012-11-08 CA CA2855005A patent/CA2855005C/en active Active
- 2012-11-08 BR BR112014011336A patent/BR112014011336A2/en not_active Application Discontinuation
- 2012-11-08 AU AU2012335803A patent/AU2012335803B2/en active Active
- 2012-11-08 WO PCT/US2012/064075 patent/WO2013070861A1/en active Application Filing
- 2012-11-08 MY MYPI2014001376A patent/MY182553A/en unknown
- 2012-11-08 EP EP17156230.9A patent/EP3184110B1/en active Active
- 2012-11-08 DK DK12784857.0T patent/DK2776034T3/en active
- 2012-11-08 SG SG10201609145PA patent/SG10201609145PA/en unknown
- 2012-11-08 RU RU2014122758A patent/RU2630978C2/en active
- 2012-11-08 EP EP20193075.7A patent/EP3763370A1/en not_active Withdrawn
- 2012-11-08 MX MX2014005640A patent/MX350662B/en active IP Right Grant
- 2012-11-08 US US13/672,475 patent/US20130123303A1/en not_active Abandoned
- 2012-11-08 EP EP12784857.0A patent/EP2776034B1/en active Active
- 2012-11-09 TW TW108123351A patent/TW202014189A/en unknown
- 2012-11-09 TW TW101141967A patent/TWI580424B/en active
- 2012-11-09 TW TW106103338A patent/TWI708604B/en active
- 2012-11-12 AR ARP120104260A patent/AR088845A1/en unknown
-
2014
- 2014-05-07 IL IL232483A patent/IL232483B/en active IP Right Grant
- 2014-05-12 ZA ZA2014/03396A patent/ZA201403396B/en unknown
- 2014-05-12 CL CL2014001242A patent/CL2014001242A1/en unknown
-
2015
- 2015-05-01 US US14/702,219 patent/US9308201B2/en active Active
- 2015-10-30 US US14/927,948 patent/US20160051534A1/en not_active Abandoned
-
2016
- 2016-08-17 AU AU2016216627A patent/AU2016216627B2/en active Active
- 2016-11-16 US US15/353,262 patent/US20170095466A1/en not_active Abandoned
-
2017
- 2017-05-08 JP JP2017092572A patent/JP6526737B2/en active Active
-
2018
- 2018-08-21 IL IL261269A patent/IL261269A/en unknown
-
2019
- 2019-08-18 IL IL26875719A patent/IL268757A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236221A (en) | Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases | |
| HK1199099A1 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| EP2621499A4 (en) | Methods for the treatment of allergic diseases | |
| PL2643004T3 (en) | Oligosaccharide composition for treating skin diseases | |
| HUE037600T2 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| MX349004B (en) | New compounds. | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| IL268757A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| EP2654745A4 (en) | Composition for the treatment of skin conditions | |
| EP2723924A4 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
| HK1198909A1 (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| EP2691529A4 (en) | Methods and compositions for treating brain diseases | |
| PT2539352T (en) | Amp derivatives for treating cardiac diseases | |
| HK1197235A1 (en) | Dihydropyrazoles, pharmaceutical compositions thereof and their use for the treatment of fertility disorders | |
| HK1210163A1 (en) | Compositions and methods for treating or preventing pneumovirus infection and associated diseases | |
| EP2709632A4 (en) | Compositions and methods for the treatment of skin diseases | |
| PL392436A1 (en) | Arylsulphonamide derivatives for treating the diseases of the central nervous system | |
| EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
| EP2872166A4 (en) | Compositions and methods for detecting, treating and preventing diseases and disorders | |
| IL225755A0 (en) | 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain | |
| PL395469A1 (en) | Indolamines derivatives for the treatment of diseases of the central nervous system | |
| EP2578206A4 (en) | Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system | |
| PL2456445T3 (en) | Agent for the treatment of skin conditions | |
| HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases |